Self.co develops and manufactures proprietary microarray blood tests that measure immune responses to 98 airborne allergens and 220 food sensitivities, giving users molecular-level insights for €69–€99 versus the €200–€400 charged by traditional labs. The company controls the entire workflow—from biomarker development to laboratory analysis—allowing it to cut intermediaries and deliver faster, lower-cost results. Its digital service pairs these lab-grade tests with AI-driven reports that include personalised avoidance plans, supplement recommendations, and referrals to partner healthcare providers. Self.co is among the few firms worldwide capable of producing molecular allergy tests with roughly 100 analytes. With the new capital, the team plans to expand distribution into the UK, Ireland, Austria, and Germany while deepening collaborations with healthcare systems in Poland and Lithuania. Funds will also support R&D to refine its testing technology, integrate advanced symptom questionnaires, and broaden its test menu within a comprehensive digital health platform. No revenue or user figures were disclosed, but the company positions itself to serve the 30–40 % of the global population affected by allergies and intolerances.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2025